States target pharmacy benefit managers with new laws to lower prescription drug costs
By
John Hanna
Summary
States across the U.S. are passing laws to regulate pharmacy benefit managers (PBMs) — middlemen that manage prescription drug coverage for health insurers — in an effort to lower medication costs for consumers. At least a dozen states enacted laws this year limiting PBM compensation and setting minimum payments. CVS Health Corp., which operates a major PBM and also owns retail pharmacies, has spent millions fighting these regulations and filed a federal lawsuit arguing a new Tennessee law could force it to close all 136 of its pharmacies there by July 2028. The issue is politically charged ahead of midterm elections, with affordability being a key voter concern.
Source
Key quotes
· 3 pulledCVS Health Corp. operates a large pharmacy benefit manager and says a new Tennessee law could force CVS to close all 136 of its retail pharmacies there in July 2028.
Affordability is a key issue ahead of this year's midterm elections, and lawmakers in at least a dozen states passed laws this year targeting pharmacy benefit managers.
CVS has spent millions of dollars fighting the regulations.
You might also wanna read
Research Reveals Persistent Drug Pricing Distortions from PBM-Owned Pharmaceutical Companies
The article examines the persistent distortions in U.S. drug pricing, particularly focusing on vertically integrated pharmacy benefit manage
Senators Investigate Pharmaceutical Companies' Direct-to-Consumer Telehealth Platforms for Steering Patients to High-Cost Drugs
U.S. senators are investigating direct-to-consumer (DTC) telehealth platforms operated by pharmaceutical companies like Eli Lilly and Pfizer
arstechnica.com·4mo ago
TrumpRx Website Launches for Direct-to-Consumer Prescription Drug Sales
The article announces the launch of TrumpRx, a government-run website where drug manufacturers will sell prescription medicines directly to
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·7mo agoU.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec

White House Launches TrumpRx Direct-to-Consumer Drug Pricing Website
The White House has launched TrumpRx, a direct-to-consumer drug pricing website that allows patients to purchase certain medications at disc

Comments
Sign in to join the conversation.
No comments yet. Be the first.